Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.30 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.30 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.30 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.30 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.30 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.30 |
| ▸ | REN | P00797 | 2/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4412655 | 1.00 | MGLL (0.31) | MGLLPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL2323495 | 1.00 | MGLL (0.31) | MGLLPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL2023160 | 0.86 | PSEN1 (0.31) | MGLLPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL2326663 | 0.86 | PSEN1 (0.31) | MGLLPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1870238 | 0.86 | CTSK (0.37) | — | |
| SCHEMBL4200774 | 0.85 | PSEN1 (0.33) | MGLLPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL2028956 | 0.85 | PSEN1 (0.33) | MGLLPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL498956 | 0.81 | PSEN1 (0.31) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1866875 | 0.78 | — | — | |
| SCHEMBL499680 | 0.76 | ATM (0.38) | RENCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081927-B1 | PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | VITAE PHARMACEUTICALS INC (US) | 2011-08-17 | — | — | EP | claimed |
| US-20090318501-A1 | Piperidine derivatives as renin inhibitors | VITAE PHARMACEUTICALS, INC. | 2009-12-24 | — | — | US | claimed |
| EP-2081927-B1 | PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | VITAE PHARMACEUTICALS INC (US) | 2011-08-17 | — | — | EP | disclosed |
| US-20090318501-A1 | Piperidine derivatives as renin inhibitors | VITAE PHARMACEUTICALS, INC. | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318501-A1 | Piperidine derivatives as renin inhibitors | ACE, DNPEP, PEPD | MGLL 2353/4885PSEN1 303/4885PSEN2 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.